Try a new search

Format these results:

Searched for:



Total Results:


B-cell lymphoma of the vagina occurring after treatment for classic Hodgkin lymphoma: A case report and literature review

Chen, X; Hamele-Bena, D; Fai, Chow K; Hawver, M; He, H; Raphael, B; Jain, S; Wright, TC
Malignant lymphomas of the female genital tract are very uncommon, and the development of a diffuse large B-cell lymphoma involving the vagina following treatment for classic Hodgkin lymphoma is extremely rare. Clinically and morphologically, this entity represents a challenge. We herein report such a case with liquid-based Pap test and tissue biopsy findings. Diagn. Cytopathol. 2011;. (c) 2011 Wiley-Liss, Inc.
PMID: 21953901
ISSN: 1097-0339
CID: 157312

Hematological disorders

Chapter by: Raphael, Bruce G
in: Medical aspects of disability : a handbook for the rehabilitation professional by Flanagan, Steven R; Zaretsky, Herbert H; Moroz, Alex [Eds]
New York : Springer, c2011
pp. 223-236
ISBN: 0826127843
CID: 5787

Sustained, durable responses with alemtuzumab in refractory angioimmunoblastic T-cell lymphoma [Letter]

Amengual, Jennifer E; Raphael, Bruce G
PMID: 20572801
ISSN: 1042-8194
CID: 157313

Postchemotherapy histiocyte-rich pseudotumor involving the spleen [Case Report]

Chandra, Pranil; Wen, Yong Hannah; Tuli, Sandeep; Raphael, Bruce G; Amorosi, Edward L; Medeiros, L Jeffrey; Ibrahim, Sherif
We report 2 cases of splenic postchemotherapy histiocyte-rich pseudotumor. Each patient had a history of diffuse large B-cell lymphoma, treated with multiagent chemotherapy. Computed tomography scans performed on both patients showed splenic masses. A positron emission tomography scan performed on 1 patient showed increased metabolic activity. The preoperative diagnosis in both patients was recurrent lymphoma, prompting splenectomy. The splenectomy specimens showed multiple, tan-white, firm nodules, up to 3.5 cm in diameter, that were histologically composed of central necrotic B cells (CD20+/CD3-), consistent with necrotic lymphoma, surrounded by numerous lipid-laden (xanthomatous) histiocytes. Clinical staging studies at the time of splenectomy showed no other sites of disease. We conclude that these histologic and immunophenotypic findings represent chemotherapy-induced tumor necrosis with a florid histiocytic reaction mimicking residual viable lymphoma. Others have used descriptive terminology or the term xanthomatous pseudotumor for these lesions that have been only rarely reported in the spleen previously
PMID: 19687310
ISSN: 1943-7722
CID: 114480

Is JAK2 inducible by cytotoxic chemotherapy? [Meeting Abstract]

Bendaly E.A.; Rahman S.S.; Zafar S.; Haglof K.; Ibrahim S.; Raphael B.G.
Introduction: The JAK2<sup>V617F</sup> mutation accounts for most cases of myeloproliferative neoplasms (MPN). Only a few case reports of MPN following cytotoxic chemotherapy have been reported, and all of them were published prior to the discovery of the JAK2 <sup>V617F</sup> mutation. We report a series of 6 patients who developed a JAK2 <sup>V617F</sup> positive MPN following cytotoxic chemotherapy. Patients: From 2006 to 2009, 6 patients with a history of a hematologic or an oncologic malignancy who developed an MPN were identified and their medical records retrospectively reviewed. One patient had acute lymphoblastic leukemia, 1 had Hodgkin lymphoma, 1 had squamous cell carcinoma of the head and neck, 1 had cervical cancer, and 2 had breast cancer. All patients were in remission from their primary malignancies at the time the MPN was diagnosed. Five were females. The median age at diagnosis was 72 years. Median time to development of the myeloproliferative neoplasm was 14 years. Type of chemotherapy exposure, MPN diagnosis and time to MPN in each case is shown in the table below. The JAK2 <sup>V617F</sup> mutation was detected either in the peripheral blood or the bone marrow of all patients. There was no predominance of any specific MPN diagnosis. Patients who received platinum-based chemotherapy developed the MPN sooner than those who received alkylators (6 vs 17.5 years respectively). Treatment consisted of phlebotomy, hydroxyurea, anagrelide, aspirin or a combination as deemed appropriate by the treating hematologist. Conclusion: These findings lead us to hypothesize whether the development of JAK2 <sup>V617F</sup> positive MPN may be related to prior exposure to cytotoxic chemotherapy. Exposure to platinum-based chemotherapy may cause the disorder to appear sooner compared with exposure to alkylators. Recently, JAK2 <sup>V617F</sup> positive MPN was found to be strongly associated with a specific constitutional haplotype, 46/1<sup>1</sup> suggesting increased susceptibility to this mutation. Chromosomal analyses are planned to show whether any of the reported patients exhibit this haplotype.(Table presented)
ISSN: 0006-4971
CID: 112215

Diffuse ground-glass opacities in a patient with Hodgkin lymphoma and progressive respiratory failure [Case Report]

Godoy, Myrna C B; Nonaka, Daisuke; Raphael, Bruce G; Vlahos, Ioannis
PMID: 18628228
ISSN: 0012-3692
CID: 81066

Simultaneous plasmablastic myeloma and high-grade follicular lymphoma: Clonal relatedness and therapeutic implications [Meeting Abstract]

Chandra, P; Liu, C; Raphael, B; Ishmaili, N; Ibrahim, S
ISSN: 1525-1578
CID: 87180

Hematologic Disorders

Chapter by: Raphael, Bruce G
in: Medical aspects of disability : a handbook for the rehabilitation professional by Zaretsky, Herbert H [Eds]
New York, NY, US: Springer Publishing Co, 2005
pp. 325-341
ISBN: 0826179738
CID: 4098

FDG positron emission tomography of bone involvement in sarcoidosis [Case Report]

Aberg, Caroline; Ponzo, Fabio; Raphael, Bruce; Amorosi, Edward; Moran, Victor; Kramer, Elissa
PMID: 15039174
ISSN: 0361-803x
CID: 43828

Correlation between percentage of aspirated blasts and myelofibrosis (MF) in high-grade myelodysplasia (MDS) [Meeting Abstract]

Fan, Y; Hymes, K; Raphael, B; Inghirami, G; Tiesinga, J
ISSN: 0023-6837
CID: 55192